All Oncology News

The CHMP has recommended a conditional approval for ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with multiple myeloma who have received at least 1 prior therapy.

The Committee for Medicinal Products for Human Use has recommended approval of palbociclib for patients with HR-positive, HER2-negative metastatic breast cancer, either in combination with an aromatase inhibitor in the frontline setting, or combined with fulvestrant after progression on endocrine therapy.

The Committee for Medicinal Products for Human Use has recommended approval of the PDGFRα antagonist olaratumab for use in combination with doxorubicin for patients with advanced soft tissue. sarcoma who are not good candidates for radiotherapy or surgery.

The European Commission has approved lenvatinib (Kisplyx) in combination with everolimus for patients with advanced renal cell carcinoma following 1 prior VEGF-targeted therapy.

Improved understanding of Waldenström's macroglobulinemia and expanded treatment options have made individualized treatment based on clinical indications a feasible strategy

The PD-L1 inhibitor atezolizumab has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

It is important to achieve a complete and thorough understanding of triple-negative breast cancer in order to most effectively treat patients.

The European Commission has approved cabozantinib for the treatment of patients with advanced renal cell carcinoma after the failure of VEGF-targeted therapy, according to Exelixis and Ipsen, the manufacturers of the multikinase inhibitor.

Despite multiple therapeutic advances in recent years, proteasome inhibitors remain a cornerstone of therapy for multiple myeloma, both newly diagnosed and relapsed and refractory disease.

The FDA’s Oncologic Drugs Advisory Committee voted 14-0 against approving apaziquone (EOquin; Qapzola) for intravesical instillation immediately following transurethral resection in patients with non-muscle invasive bladder cancer.

Several variables are important to consider when undergoing preventive surgery for ovarian cancer, including familial history and age.

Chimeric antigen receptor T-cells offer highly effective therapy for patients with minimal residual disease or bulky disease in both aggressive and indolent B-cell non-Hodgkin lymphomas.

Recent success with novel agents for chronic lymphocytic leukemia has spurred development of more agents in the same therapeutic classes; however, definitive advantages over the originals have yet to be established.

After updated findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial were presented earlier this year, members of the oncology community strongly suggested that the United States Preventative Services Task Force revise its views on prostate-specific antigen screening for patients with prostate cancer.

The future of imetelstat as a treatment for patients with myelodysplastic syndromes is uncertain following an update on 2 clinical trials.

Almost 90% of patients with previously treated light chain amyloidosis responded to single-agent daratumumab (Darzalex).

The FDA has granted a fast track designation to niraparib, allowing the initiation of a rolling submission of data for potential approval for the PARP inhibitor as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Combining the BCL-2 inhibitor venetoclax (Venclexta) with the anti-CD20 agent rituximab (Rituxan) led to objective responses in 86% of patients with relapsed/refractory chronic lymphocytic leukemia.

The Wistar Institute, an international leader in cancer, immunology and infectious diseases research, is pleased to announce that Ashani Weeraratna, PhD, associate professor and program leader in the Tumor Microenvironment and Metastasis Program, has been named the Ira Brind Associate Professor.

Evidence has demonstrated that obesity is a risk factor for clear cell renal cell carcinoma; however, a new report suggests that a high body mass index is a prognostic factor for improved survival in patients with metastatic RCC who have received targeted therapy.

CMS has scaled back the implementation of physician reporting requirements under the Quality Payment Program of medical value improvement created under the Medicare Access and CHIP Reauthorization Act legislation.

Currently available therapies offer meaningful clinical benefits to patients with myelofibrosis, but achieving remission will likely require new molecules targeting different pathways.

Diagnostic criteria and therapeutic strategies for myelodysplastic and myeloproliferative neoplasms continue to evolve as molecular and genetic studies have provided new insights into the diseases.

Neoadjuvant chemotherapy is likely the optimal treatment choice for some women with newly diagnosed advanced ovarian cancer, while other patients should receive primary cytoreductive surgery.

Clinical experience with lenalidomide (Revlimid) in myelodysplastic syndromes has provided evidence of potential to improve survival and reduce the leukemic progression in patients with 5q-deletion.

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a first-line treatment for patients with PD-L1–positive non–small cell lung cancer.

Vaginal brachytherapy has been linked to improved survival in women with stage I endometrioid adenocarcinoma of the uterus.

Selinexor (KPT-330) demonstrated promising clinical activity in patients with heavily pretreated multiple myeloma.

An international leader in harnessing a patient's own stem cells to fight cancer and autoimmune diseases joined the faculty of the University of Wisconsin Carbone Cancer Center on September 1.